FSHD region gene 2 family member K, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FRG2KP profile across patient tissues and cancer cell-line models. FRG2KP expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FRG2KP is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, FRG2KP RNA expression shows 6,535 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, and STAD as cancer lineages where FRG2KP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRG2KP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRG2KP survival associations across molecular data types. FRG2KP RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRG2KP RNA expression–survival associations across cancer types. High FRG2KP expression shows unfavorable associations in DLBC, READ, STAD, MESO and ESCA, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .014). Together, the overview and detailed table identify HNSC as the clearest survival context for FRG2KP RNA expression.
This table summarizes FRG2KP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FRG2KP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRG2KP shows higher tumor expression in HNSC. The HNSC box plot shows higher FRG2KP RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .016).
This table shows molecular features associated with FRG2KP in patient tissues and cancer cell lines. In patient samples, FRG2KP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
